Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc has demonstrated a noteworthy potential for revenue growth through its new selling model, which is projected to generate 4-6 times more revenue per case while also accessing a substantially larger patient base and maintaining healthy margins. The company's strategic initiatives, including positive pilot results with Rebis Health, suggest that Vivos is actively pursuing partnerships and acquisitions with sleep testing centers nationwide, thereby enhancing its market presence. Despite a significant increase in operating expenses, the company's business model transformation and expansion strategies indicate a favorable long-term outlook for growth and profitability.

Vivos Therapeutics Inc. reported Q2 FY25 revenues of $3.8 million, which fell short of expectations and marked a 6% year-over-year decline despite a 27% quarter-over-quarter improvement, highlighting challenges during the company's transition to the sleep center channel. Additionally, the company has revised its FY25 earnings per share (EPS) estimates downward to $(2.13) from $(1.54), citing higher operating expenses, with actual pro forma EPS reported at $(0.55), significantly below both internal and consensus estimates. Furthermore, concerns regarding low visibility for future performance and potential further dilution from financing sources contribute to an overall negative outlook on the stock.